Company profile: Acrivon Therapeutics
1.1 - Company Overview
Company description
- Provider of precision oncology therapeutics and companion diagnostics, leveraging the AP3 platform to develop drugs and OncoSignature tests that match therapies to tumor-driving mechanisms. Pipeline includes ACR-368, a phase 2 DNA damage response kinase inhibitor for solid cancers, and ACR-2316, a preclinical selective dual WEE1/PKMYT1 inhibitor.
Products and services
- ACR-368: A clinically-advanced kinase inhibitor targeting the DNA Damage Response, in phase 2 development for treating solid cancers
- OncoSignature tests: Proprietary companion diagnostics developed using the AP3 platform to match therapies with patients based on tumor-driving mechanisms
- AP3 platform: A precision medicine platform that engineers preclinical and clinical-stage pipeline programs, including drug and companion diagnostic development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Acrivon Therapeutics
Vortex Biosciences
HQ: United States
Website
- Description: Provider of oncology diagnostics integrating cancer biology, microfluidic engineering, and informatics to isolate and characterize circulating tumor cells (CTCs). Offers the VTX-1 Liquid Biopsy System for label-free isolation of viable CTCs from blood, CTC enrichment using disposable cartridges, CTC analysis and downstream assays, and cell handling in formats compatible with different workflows.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vortex Biosciences company profile →
Enara Bio
HQ: United Kingdom
Website
- Description: Provider of cancer immunotherapy solutions targeting the T-cell/cancer cell interface, offering the EDAPT platform to discover cancer-specific Dark Antigens, TCR-directed immunotherapies, and off-the-shelf therapeutic cancer vaccines targeting multiple Dark Antigens for broad patient populations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enara Bio company profile →
Lymphatica Medtech
HQ: Switzerland
Website
- Description: Provider of medical device development, creating a minimally invasive solution for chronic lymphedema.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lymphatica Medtech company profile →
Circio
HQ: Norway
Website
- Description: Provider of active immunotherapy cancer vaccines for post-operation treatments, including TG01, a peptide-based vaccine targeting KRAS/RAS driver mutations in clinical trials for RAS-mutated pancreatic cancer, lung cancer, and multiple myeloma, and circVec, a genetic medicine platform producing multifunctional circular RNA from DNA and viral vectors with enhanced, durable protein expression versus classic mRNA systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Circio company profile →
Tilos Therapeutics
HQ: United States
Website
- Description: Provider of antibody therapeutics targeting key immunological pathways, with a focus on regulatory T cells and effector cell regulation; developing anti-LAP antibodies specific to the Latency Associated Peptide of TGF beta for cancer treatment. Founded in 2016 and based in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tilos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Acrivon Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Acrivon Therapeutics
2.2 - Growth funds investing in similar companies to Acrivon Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Acrivon Therapeutics
4.2 - Public trading comparable groups for Acrivon Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →